Table 1.

Inclusion and exclusion criteria

Inclusion criteria
1	Patients with familial cerebral cavernous malformations (FCCM)
2	History of clinical symptoms or events: ICH, seizures, stroke, permanent or transient focal deficits, intellectual disability, or any other neurological symptoms supposedly related to CCM
3	Age ≥18 years
4	Written informed consent to participate in the study prior to any study procedures
Exclusion criteria
1	Implanted pacemaker or any other condition preventing the MRI examination
2	Bradycardia (< 50 bpm), second or third-degree AV block or symptomatic hypotension
3	Unstable diabetes
4	Severe asthma
5	Liver and/or renal failure
6	Current use of verapamil or diltiazem for risk of excessive bradycardia
7	Previous brain surgery (within 6 months)
8	Known hypersensitivity to study drug (propranolol or any of the ingredients)
9	Pregnant or lactating women, or women at risk of childbearing who are not under protection by an accepted method of contraception
10	Participation to another clinical trial
11	Inability to cooperate with the trial procedures
In addition to these specific exclusion criteria, all well-documented contraindications to beta-blocker use are also valid in this trial

AV atrioventricular, CCM cerebral cavernous malformation, ICH intracerebral haemorrhage, MRI magnetic resonance imaging